Methods of detecting collagen degradation in vivo
AssigneeWashington Research Foundation
InventorDavid R. Eyre
Life of this patent
Estimating the term…
Abstract
A method of determining collagen degradation in vivo, comprising quantitating the concentration of a peptide in a body fluid, the peptide being a C-terminal type II collagen telopeptide containing a hydroxylysyl pyridinoline cross-link or a type III collagen telopeptide containing a hydroxylysyl pyridinoline cross-link. The method includes immunometric assays, fluorometric assays, and electrochemical titrations for quantitation. The structures of specific peptides having cross-links and kits for quantitating these peptides in a body fluid are described.
Claims15
A method of determining cartilage degradation in vivo, comprising quantitating the concentration of a peptide in a body fluid sample, said peptide comprising:
- ##STR19## wherein ##STR20## is hydroxylysyl pyridinoline.
A method of determining collagenous connective tissue degradation in vivo, comprising quantitating the concentration of a peptide in a body fluid sample, said peptide comprising:
- ##STR23## wherein ##STR24## is hydroxylysyl pyridinoline.
In a method of analyzing body fluids for the presence of an analyte indicative of a physiological condition, comprising the steps of contacting the body fluid with a specific binding partner for said analyte, and detecting any binding that occurs between the analyte and the specific binding partner, the improvement comprising contacting the body fluid with at least one immunological binding partner specific for a peptide comprising:
- ##STR25## wherein ##STR26## is hydroxylysyl pyridinoline.
In a method of analyzing body fluids for the presence of an analyte indicative of a physiological condition, comprising the steps of contacting the body fluid with a specific binding partner for said analyte, and detecting any binding that occurs between the analyte and the specific binding partner, the improvement comprising contacting the body fluid with at least one immunological binding partner specific for a peptide comprising:
- ##STR27## wherein ##STR28## is hydroxylysyl pyridinoline.
A test kit comprising one or more immunological binding partners that specifically bind to a peptide comprising:
- ##STR29## wherein ##STR30## is hydroxylysyl pyridinoline.
A test kit comprising one or more immunological binding partners that specifically bind to a peptide comprising:
- ##STR31## wherein ##STR32## is hydroxylysyl pyridinoline.
Dependencies are inferred from the claim text.